OCEA (Ocean Biomedical) Total Liabilities: $93.98 Mil (As of Mar. 2025)


What is Ocean Biomedical Total Liabilities?

Ocean Biomedical OCEA -66.67% Total Liabilities is $93.98 Mil as of Mar. 2025.

Ocean Biomedical's Total Liabilities for the quarter that ended in Mar. 2025 was $93.98 Mil.

Ocean Biomedical's quarterly Total Liabilities declined from Sep. 2024 ($99.22 Mil) to Dec. 2024 ($98.52 Mil) and declined from Dec. 2024 ($98.52 Mil) to Mar. 2025 ($93.98 Mil).

Ocean Biomedical's annual Total Liabilities increased from Dec. 2022 ($12.66 Mil) to Dec. 2023 ($96.26 Mil) and increased from Dec. 2023 ($96.26 Mil) to Dec. 2024 ($98.52 Mil).

Ocean Biomedical Total Liabilities Historical Data

* Premium members only.

The historical data trend for Ocean Biomedical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocean Biomedical Total Liabilities Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial 2.27 3.40 12.66 96.26 98.52

Ocean Biomedical Quarterly Data
Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.73 94.59 99.22 98.52 93.98

Ocean Biomedical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ocean Biomedical's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=33.889+(0+64.629
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=98.52

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=0.902--97.616
=98.52

Ocean Biomedical's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=26.568+(0+67.413
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=93.98

Total Liabilities=Total Assets (Q: Mar. 2025 )-Total Equity (Q: Mar. 2025 )
=1.582--92.399
=93.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $93.98 Mil mean?
Ocean Biomedical (OCEA) has a Total Liabilities of $93.98 Mil as of Mar. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ocean Biomedical and its competitors.
Is Ocean Biomedical's Total Liabilities too high?
Ocean Biomedical's current Total Liabilities is $93.98 Mil.
How does Ocean Biomedical's Total Liabilities compare to SIGY and ENDV?
Ocean Biomedical's Total Liabilities of $93.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ocean Biomedical and its competitors. Ocean Biomedical's current Total Liabilities is $93.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocean Biomedical stock overvalued right now?
Ocean Biomedical (OCEA) has a current Total Liabilities of $93.98 Mil. The current Total Liabilities is $93.98 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ocean Biomedical (OCEA), the current Total Liabilities is $93.98 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ocean Biomedical Business Description

Address 55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.